The hRVFV-4s vaccine showed a high safety profile and excellent tolerability across all tested dose regimens, eliciting robust immune responses, particularly with the high-dose administration. The findings strongly support further clinical development ...
Knowledge of classical and next-generation vaccine principles has improved considerably over the past two decades. This expertise has enabled the development of vaccines against various infectious diseases, including principles such as whole inactivate...
The increasing host range and ability of avian influenza viruses to spread between mammals and humans raises concerns about a potential pandemic risk.1 This pandemic risk is a concern as the mortality was 458 (52%) of the 876 influenza A(H5N1) cases re...
The increasing host range and ability of avian influenza viruses to spread between mammals and humans raises concerns about a potential pandemic risk.1 This pandemic risk is a concern as the mortality was 458 (52%) of the 876 influenza A(H5N1) cases re...
In their study, Alimuddin Zumla and colleagues1 highlighted the potential threat of MERS-related coronaviruses (MERSr-CoV, subgenus Merbecovirus) to global health. A key concern is the ability of the virus to use diverse cell entry receptors, including...
In their study, Alimuddin Zumla and colleagues1 highlighted the potential threat of MERS-related coronaviruses (MERSr-CoV, subgenus Merbecovirus) to global health. A key concern is the ability of the virus to use diverse cell entry receptors, including...
Most of the 6 million fungal species estimated to live on Earth remain unidentified. In his new book What if fungi win?, Arturo Casadevall explores what our uncertainty around fungal species' variability could mean—for better or worse—in a future, warm...
Most of the 6 million fungal species estimated to live on Earth remain unidentified. In his new book What if fungi win?, Arturo Casadevall explores what our uncertainty around fungal species' variability could mean—for better or worse—in a future, warm...
Artemisinin-based combination therapy (ACT) has been the mainstay for uncomplicated Plasmodium falciparum malaria globally for over 15 years. ACT was considered crucial to prevent the development of resistance to either compound, but it did not prevent...
Africa faces numerous health challenges, straining the continent's limited health services. Emerging threats, such as Ebola, mpox, and frequent cholera outbreaks highlight the need for a proactive, coordinated, and unified approach to infectious diseas...
The heterologous Ad26.Mos4.HIV and clade C gp140 vaccine regimen was safe and well tolerated but did not show efficacy in preventing HIV-1 acquisition in a population of young women in southern Africa at risk of HIV-1.
With approximately 1·3 million new HIV type 1 (HIV-1) infections still occurring annually, there is an urgent need for an effective vaccine against HIV-1 acquisition.1 Since the first vaccine trials in the late 1980s, a variety of vaccine strategies ha...
On Nov 10, 2023, the Joint Committee on Vaccination and Immunisation advised the UK to use the 4CMenB meningitis B vaccine to prevent gonorrhoea in men who have sex with men on the basis of an estimated effectiveness of 33–47% from multiple observation...
On Nov 10, 2023, the Joint Committee on Vaccination and Immunisation advised the UK to use the 4CMenB meningitis B vaccine to prevent gonorrhoea in men who have sex with men on the basis of an estimated effectiveness of 33–47% from multiple observation...
A booster dose of VLA15 is safe and induces substantial anamnestic immune responses against all six OspA serotypes. As with previously investigated OspA-based Lyme borreliosis vaccines, waning immune responses were observed with VLA15, and annual boost...
A booster dose of VLA15 is safe and induces substantial anamnestic immune responses against all six OspA serotypes. As with previously investigated OspA-based Lyme borreliosis vaccines, waning immune responses were observed with VLA15, and annual boost...